Type : | Industriel |
Statut : | Ouvert |
Phase : | I |
Étape du traitement : | Thérapie ciblée |
Date d'ouverture : | 09/07/2019 |
Date clôture : | 31/07/2024 |
Promoteur : | Dizal Pharmaceuticals |
Progression du cancer: | Loco-régional et à distance |
Résumé :
This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.
Domaines/spécialités :
- Cancers thoraciques respiratoires
- Cancer bronchique non à petites cellules
Biomarqueurs :
- HER2
- EGFR
Pathologies :
- Tumeur maligne des bronches et du poumon - Cim10 : C34
Liens externes :